Pavlidis P., Komorowski L., Teegen B., Liaskos C., Koutsoumpas A.L., Smyk D.S., Perricone C., Mytilinaiou M.G., Stocker W., Forbes A., Bogdanos D.P. (2016)
Background: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of ...